☰

Ingunn M. Stromnes, Ph.D. - Publications

Affiliations: 
2007 University of Washington, Seattle, Seattle, WA 
Area:
Immunology
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Tsai AK, Stromnes IM. CD39 deletion in TCR-engineered T cells enhances antitumour immunity. Gut. PMID 37898545 DOI: 10.1136/gutjnl-2023-330424  0.523
2023 Patterson MT, Burrack AL, Xu Y, Hickok GH, Schmiechen ZC, Becker S, Cruz-Hinojoza E, Schrank PR, Kennedy AE, Firulyova MM, Miller EA, Zaitsev K, Williams JW, Stromnes IM. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Cell Reports. 42: 112732. PMID 37402168 DOI: 10.1016/j.celrep.2023.112732  0.499
2023 Stromnes IM. IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer. Cancer Immunology Research. OF1. PMID 36897261 DOI: 10.1158/2326-6066.CIR-23-0145  0.497
2023 Rollins MR, Raynor JF, Miller EA, Butler JZ, Spartz EJ, Lahr WS, You Y, Burrack AL, Moriarity BS, Webber BR, Stromnes IM. Germline T cell receptor exchange results in physiological T cell development and function. Nature Communications. 14: 528. PMID 36726009 DOI: 10.1038/s41467-023-36180-1  0.861
2022 Burrack AL, Spartz EJ, Rollins MR, Miller EA, Firulyova M, Cruz E, Goldberg MF, Wang IX, Nanda H, Shen S, Zaitsev K, Stromnes IM. Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate. Cancer Immunology, Immunotherapy : Cii. PMID 36472588 DOI: 10.1007/s00262-022-03338-7  0.881
2022 Burrack AL, Schmiechen ZC, Patterson MT, Miller EA, Spartz EJ, Rollins MR, Raynor JF, Mitchell JS, Kaisho T, Fife BT, Stromnes IM. Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer. Jci Insight. 7. PMID 35393950 DOI: 10.1172/jci.insight.151593  0.87
2022 Stromnes IM, Hulbert A, Rollins MR, Basom RS, Delrow J, Bonson P, Burrack AL, Hingorani SR, Greenberg PD. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer. Journal For Immunotherapy of Cancer. 10. PMID 35210305 DOI: 10.1136/jitc-2021-003525  0.863
2021 Burrack AL, Rollins MR, Spartz EJ, Mesojednik TD, Schmiechen ZC, Raynor JF, Wang IX, Kedl RM, Stromnes IM. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. Journal of Immunology (Baltimore, Md. : 1950). PMID 33558374 DOI: 10.4049/jimmunol.2000765  0.858
2020 Schmiechen ZC, Stromnes IM. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Frontiers in Immunology. 11: 613815. PMID 33584701 DOI: 10.3389/fimmu.2020.613815  0.676
2020 Schmiechen ZC, Burrack AL, Stromnes IM. Chemotherapy brings virtual memory T cells into reality for cancer therapy. Cellular & Molecular Immunology. PMID 32620786 DOI: 10.1038/S41423-020-0496-6  0.51
2020 Cole KE, Ly QP, Hollingsworth MA, Cox JL, Stromnes IM, Padussis JC, Foster JM, Vargas LM, Talmadge JE. Comparative phenotypes of peripheral blood and spleen cells from cancer patients. International Immunopharmacology. 85: 106655. PMID 32521493 DOI: 10.1016/J.Intimp.2020.106655  0.691
2020 Rollins MR, Spartz EJ, Stromnes IM. T Cell Receptor Engineered Lymphocytes for Cancer Therapy. Current Protocols in Immunology. 129: e97. PMID 32432843 DOI: 10.1002/Cpim.97  0.87
2020 Burrack AL, Rollins MR, Spartz EJ, Raynor JF, Wang I, Mitchell J, Kaisho T, Fife B, Kedl R, Shen S, Stromnes IM. Abstract NG12: Mechanisms governing efficacy of combination CD40 agonist and anti-PD-L1 in pancreatic ductal adenocarcinoma Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ng12  0.587
2019 Burrack AL, Spartz EJ, Raynor JF, Wang I, Olson M, Stromnes IM. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Cell Reports. 28: 2140-2155.e6. PMID 31433988 DOI: 10.1016/J.Celrep.2019.07.059  0.575
2019 Anderson KG, Voillet V, Bates B, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD. Engineered adoptive T-cell therapy prolongs survival in a preclinical model of advanced stage ovarian cancer. Cancer Immunology Research. PMID 31337659 DOI: 10.1158/2326-6066.Cir-19-0258  0.809
2019 Stromnes IM, Burrack AL, Hulbert A, Bonson P, Black C, Brockenbrough JS, Raynor JF, Spartz EJ, Pierce RH, Greenberg PD, Hingorani SR. Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma. Cancer Immunology Research. PMID 31028033 DOI: 10.1158/2326-6066.Cir-18-0448  0.815
2019 Anderson KG, Egan D, Hingorani SR, Oda SK, Paulson K, Perret R, Schmidt L, Schmitt T, Stromnes I, Chapuis A, Greenberg PD. Abstract IA17: Utilizing synthetic biology and high-dimensional probing to address therapeutic obstacles and empower engineered T cells with the capacity to eradicate tumors Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Ia17  0.801
2019 Greenberg PD, Anderson KG, Egan D, Hingorani SR, Nezi L, Manzo T, Oda SK, Paulson KG, Perret R, Schmidt L, Schmitt TM, Stromnes IM, Chapuis AG. Abstract I11: Targeting pancreatic cancer with TCR-engineered T cells Immunology. 79. DOI: 10.1158/1538-7445.Panca19-I11  0.729
2018 Greenberg PD, Anderson KG, Egan D, Hingorani SR, Oda SK, Perret R, Schmitt TM, Stromnes IM, Schmidt L, Chapuis AG. Abstract IA02: Engineering T cells to eradicate tumors in the age of synthetic biology Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Ia02  0.831
2017 Stromnes IM, Hulbert A, Pierce RH, Greenberg PD, Hingorani SR. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunology Research. PMID 29066497 DOI: 10.1158/2326-6066.Cir-16-0322  0.801
2017 Anderson KG, Stromnes IM, Greenberg PD. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell. 31: 311-325. PMID 28292435 DOI: 10.1016/J.Ccell.2017.02.008  0.786
2017 Greenberg PD, Chapuis A, Egan D, Stromnes I, Hingorani S, Oda S, Perret R, Anderson K, Schmitt T. Abstract IA18: Building better T cells for targeting and eliminating tumors Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-Ia18  0.809
2016 Stromnes IM, Greenberg PD. Pancreatic Cancer: Planning Ahead for Metastatic Spread. Cancer Cell. 29: 774-6. PMID 27300430 DOI: 10.1016/J.Ccell.2016.05.013  0.555
2016 Stromnes IM, Schmitt TM, Brockenbrough SJ, Nguyen H, Cuevas C, Hulbert A, Hotes J, Dotson A, Hingorani SR, Greenberg PD. Abstract IA38: Engineered T cell-receptor based therapy of pancreatic ductal adenocarcinoma Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Ia38  0.803
2016 Greenberg PD, Anderson KG, Egan D, Hingorani SR, Oda SK, Perret R, Schietinger A, Schmitt TM, Stromnes IM, Wilkens A, Chapuis AG. Abstract IA01: Engineering T cell responses to tumors: Taking the immune system where no responses have gone before Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Ia01  0.817
2015 Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen HN, Cuevas C, Dotson AM, Tan X, Hotes JL, Greenberg PD, Hingorani SR. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell. 28: 638-52. PMID 26525103 DOI: 10.1016/J.Ccell.2015.09.022  0.807
2015 Schmitt TM, Stromnes IM, Chapuis AG, Greenberg PD. New Strategies in Engineering T-cell Receptor Gene-Modified T Cells to More Effectively Target Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26463711 DOI: 10.1158/1078-0432.Ccr-15-0860  0.808
2015 Stromnes IM, Brockenbrough SJ, Schmitt TM, Hingorani SR, Greenberg PD. Abstract PR08: Enhanced affinity T cell receptor based therapy can surmount immune and physical barriers to treat pancreatic ductal adenocarcinoma Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Pr08  0.809
2015 Stromnes IM, Brockenbrough S, Schmitt TM, Hotes JD, Carlson MA, Cuevos C, Greenberg PD, Hingorani SR. Abstract PR10: Re-engineering immunity to treat pancreas cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-Pr10  0.792
2015 Brockenbrough JS, Feng L, Stromnes IM, DelGiorno KE, Whittle MC, Cuevas C, Dotson AM, Ryan JS, Thorsen SM, Hingorani SR. Abstract A92: Murine clinical trials program Cancer Research. 75. DOI: 10.1158/1538-7445.Panca2014-A92  0.377
2015 Greenberg PD, Schmitt TM, Schietinger A, Stromnes IM, Hingorani SR, Oda SK, Perret R, Anderson KG, Bar M, Chapuis AG. Abstract SY31-03: Employing TCRs in engineered T cells to develop therapeutic reagents for effectively targeting malignancies Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Sy31-03  0.814
2014 Stromnes IM, Greenberg PD, Hingorani SR. Molecular pathways: myeloid complicity in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5157-70. PMID 25047706 DOI: 10.1158/1078-0432.Ccr-13-0866  0.684
2014 Stromnes IM, DelGiorno KE, Greenberg PD, Hingorani SR. Stromal reengineering to treat pancreas cancer. Carcinogenesis. 35: 1451-60. PMID 24908682 DOI: 10.1093/Carcin/Bgu115  0.636
2014 Stromnes IM, Brockenbrough JS, Izeradjene K, Carlson MA, Cuevas C, Simmons RM, Greenberg PD, Hingorani SR. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity Gut. 63: 1769-1781. PMID 24555999 DOI: 10.1136/Gutjnl-2013-306271  0.711
2014 Pierson ER, Stromnes IM, Goverman JM. B cells promote induction of experimental autoimmune encephalomyelitis by facilitating reactivation of T cells in the central nervous system. Journal of Immunology (Baltimore, Md. : 1950). 192: 929-39. PMID 24367024 DOI: 10.4049/Jimmunol.1302171  0.802
2014 Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunological Reviews. 257: 145-64. PMID 24329795 DOI: 10.1111/Imr.12141  0.804
2013 Schmitt TM, Aggen DH, Stromnes IM, Dossett ML, Richman SA, Kranz DM, Greenberg PD. Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood. 122: 348-56. PMID 23673862 DOI: 10.1182/Blood-2013-01-478164  0.869
2013 Greenberg PD, Ochsenreither S, Schmitt T, Aggen D, Kranz D, Wolfl M, Kuball J, Majeti R, Weissman I, Stromnes I, Schietinger A, Ragnarsson G, Yee C, Bar M, Chapuis A. Abstract IA1: T cells vs. tumor cells: Arming/deploying T cells for a successful battle. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Ia1  0.831
2012 Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, Tan X, Kim TD, Choi I, Blattman JN, Greenberg PD. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. Journal of Immunology (Baltimore, Md. : 1950). 189: 1812-25. PMID 22798667 DOI: 10.4049/Jimmunol.1200552  0.857
2011 Johnson PL, Kochin BF, McAfee MS, Stromnes IM, Regoes RR, Ahmed R, Blattman JN, Antia R. Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections. Journal of Virology. 85: 5565-70. PMID 21411537 DOI: 10.1128/Jvi.00166-11  0.746
2010 Stromnes IM, Blattman JN, Tan X, Jeevanjee S, Gu H, Greenberg PD. Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice. The Journal of Clinical Investigation. 120: 3722-34. PMID 20890046 DOI: 10.1172/Jci41991  0.833
2008 Stromnes IM, Cerretti LM, Liggitt D, Harris RA, Goverman JM. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nature Medicine. 14: 337-42. PMID 18278054 DOI: 10.1038/Nm1715  0.806
2007 Stromnes IM, Goverman JM. Osteopontin-induced survival of T cells. Nature Immunology. 8: 19-20. PMID 17179966 DOI: 10.1038/Ni0107-19  0.765
2007 Stromnes I, Goverman J, Liggitt D. The Role of IL-17 and IFN-γ in Defining Pathogenic Potential of T Cells in EAE Clinical Immunology. 123: S61-S62. DOI: 10.1016/J.Clim.2007.03.354  0.751
2006 Stromnes IM, Goverman JM. Passive induction of experimental allergic encephalomyelitis. Nature Protocols. 1: 1952-60. PMID 17487182 DOI: 10.1038/Nprot.2006.284  0.74
2006 Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nature Protocols. 1: 1810-9. PMID 17487163 DOI: 10.1038/Nprot.2006.285  0.715
2004 Perchellet A, Stromnes I, Pang JM, Goverman J. CD8+ T cells maintain tolerance to myelin basic protein by 'epitope theft'. Nature Immunology. 5: 606-14. PMID 15146180 DOI: 10.1038/Ni1073  0.829
2004 Dittmer U, He H, Messer RJ, Schimmer S, Olbrich AR, Ohlen C, Greenberg PD, Stromnes IM, Iwashiro M, Sakaguchi S, Evans LH, Peterson KE, Yang G, Hasenkrug KJ. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. Immunity. 20: 293-303. PMID 15030773 DOI: 10.1016/S1074-7613(04)00054-8  0.748
2002 Peterson KE, Stromnes I, Messer R, Hasenkrug K, Chesebro B. Novel role of CD8(+) T cells and major histocompatibility complex class I genes in the generation of protective CD4(+) Th1 responses during retrovirus infection in mice. Journal of Virology. 76: 7942-8. PMID 12133998 DOI: 10.1128/Jvi.76.16.7942-7948.2002  0.492
2002 Dittmer U, Race B, Peterson KE, Stromnes IM, Messer RJ, Hasenkrug KJ. Essential roles for CD8+ T cells and gamma interferon in protection of mice against retrovirus-induced immunosuppression. Journal of Virology. 76: 450-4. PMID 11739713 DOI: 10.1128/Jvi.76.1.450-454.2002  0.554
2001 Iwashiro M, Messer RJ, Peterson KE, Stromnes IM, Sugie T, Hasenkrug KJ. Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection. Proceedings of the National Academy of Sciences of the United States of America. 98: 9226-30. PMID 11459933 DOI: 10.1073/Pnas.151174198  0.645
2001 Dittmer U, Peterson KE, Messer R, Stromnes IM, Race B, Hasenkrug KJ. Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection. Journal of Virology. 75: 654-60. PMID 11134279 DOI: 10.1128/Jvi.75.2.654-660.2001  0.347
2001 Iwashiro M, Peterson K, Messer RJ, Stromnes IM, Hasenkrug KJ. CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection. Journal of Virology. 75: 52-60. PMID 11119573 DOI: 10.1128/Jvi.75.1.52-60.2001  0.481
Show low-probability matches.